Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Nutanix Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Nutanix Inc trades at $69.61 (market cap $19.72B). The key difference: Nutanix Inc is far larger — about 6.9× Dyne Therapeutics Inc. Common Stock's market cap, and Nutanix Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Nutanix Inc for 17 Days on average.
| DYN | NTNX | |
|---|---|---|
Market Cap | $2.86B | $19.72B |
Volume | 3,341,579 | 2,236,075 |
Sector | Health | Technology |
52-Week High | $26.78 | $74.63 |
52-Week Low | $14.60 | $34.41 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $2.18B | $18.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Nutanix (NTNX) trades at $72.88, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and positive analyst sentiment. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive 86.8% gross margins. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms.
Outlook remains positive with 62.5% analyst buy ratings and $76.11 consensus price target, though elevated P/E of 14.1 and negative ROE of -395.76% warrant caution. Key risks include supply chain pressures and competitive IT services market, while AI growth initiatives and external storage expansion present upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
